Twist Bioscience Corp·4

Feb 5, 4:05 PM ET

Leproust Emily M. 4

4 · Twist Bioscience Corp · Filed Feb 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Twist Bioscience (TWST) CEO Emily Leproust Sells 5,001 Shares

What Happened

  • Emily M. Leproust, CEO of Twist Bioscience, sold 5,001 shares on 2026-02-03 at $46.58 per share, generating $232,927 in gross proceeds. The Form 4 reports this as an open-market sale (code S) and is described in the filing as a sell-to-cover to satisfy tax withholding obligations related to vesting equity.

Key Details

  • Transaction date: 2026-02-03
  • Filing date: 2026-02-05 (filed timely)
  • Price per share: $46.58
  • Shares sold: 5,001
  • Gross proceeds: $232,927
  • Footnote F1: Sale required to cover tax withholding on vested Restricted Stock Units (sell-to-cover), not a discretionary trade by the reporting person.
  • Shares owned after transaction: Not disclosed in the provided filing excerpt.
  • Other footnotes (F2–F6) in the filing describe historical option and vesting schedules for the reporting person and are informational only.

Context

  • A "sell-to-cover" is a routine transaction where the company (or issuer election) sells a portion of vested shares to cover payroll/tax withholding; such sales are common and do not necessarily indicate the insider's view of the company. Purchases generally carry more weight as signals than routine withholding sales.

Insider Transaction Report

Form 4
Period: 2026-02-03
Leproust Emily M.
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-02-03$46.58/sh5,001$232,927869,312 total
Holdings
  • Employee Stock Option (right to buy)

    [F2]
    Exercise: $5.95Exp: 2025-09-28Common Stock (0 underlying)
    0
  • Employee Stock Option (right to buy)

    [F3]
    Exercise: $8.82Exp: 2027-09-28Common Stock (0 underlying)
    150,879
  • Employee Stock Option (right to buy)

    [F4]
    Exercise: $26.66Exp: 2028-11-18Common Stock (0 underlying)
    266,539
  • Employee Stock Option (right to buy)

    [F5]
    Exercise: $23.33Exp: 2029-10-23Common Stock (0 underlying)
    131,290
  • Employee Stock Option (right to buy)

    [F6]
    Exercise: $67.85From: 2022-12-19Exp: 2030-08-31Common Stock (64,950 underlying)
    64,950
Footnotes (6)
  • [F1]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  • [F2]The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F3]The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F4]20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F5]25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F6]Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust|2026-02-05

Documents

1 file
  • 4
    marketforms-72017.xmlPrimary

    PRIMARY DOCUMENT